JP2011512394A - 慢性創傷の治療 - Google Patents
慢性創傷の治療 Download PDFInfo
- Publication number
- JP2011512394A JP2011512394A JP2010547251A JP2010547251A JP2011512394A JP 2011512394 A JP2011512394 A JP 2011512394A JP 2010547251 A JP2010547251 A JP 2010547251A JP 2010547251 A JP2010547251 A JP 2010547251A JP 2011512394 A JP2011512394 A JP 2011512394A
- Authority
- JP
- Japan
- Prior art keywords
- polyphosphate
- inhibition
- use according
- pepsin
- content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001684 chronic effect Effects 0.000 title claims abstract description 30
- 206010052428 Wound Diseases 0.000 title description 50
- 208000027418 Wounds and injury Diseases 0.000 title description 50
- 229920000388 Polyphosphate Polymers 0.000 claims abstract description 72
- 239000001205 polyphosphate Substances 0.000 claims abstract description 72
- 235000011176 polyphosphates Nutrition 0.000 claims abstract description 72
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims abstract description 13
- 230000029663 wound healing Effects 0.000 claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 102000057297 Pepsin A Human genes 0.000 claims description 34
- 108090000284 Pepsin A Proteins 0.000 claims description 34
- 229940088598 enzyme Drugs 0.000 claims description 33
- 102000004190 Enzymes Human genes 0.000 claims description 32
- 108090000790 Enzymes Proteins 0.000 claims description 32
- 229940111202 pepsin Drugs 0.000 claims description 31
- 108010003272 Hyaluronate lyase Proteins 0.000 claims description 28
- 108010067372 Pancreatic elastase Proteins 0.000 claims description 28
- 102000016387 Pancreatic elastase Human genes 0.000 claims description 28
- 229960002773 hyaluronidase Drugs 0.000 claims description 28
- 102000029816 Collagenase Human genes 0.000 claims description 20
- 108060005980 Collagenase Proteins 0.000 claims description 20
- 229960002424 collagenase Drugs 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 15
- -1 alkali metal salt Chemical class 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 229910052783 alkali metal Inorganic materials 0.000 claims description 7
- 230000009471 action Effects 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 102000001974 Hyaluronidases Human genes 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 description 54
- 235000019830 sodium polyphosphate Nutrition 0.000 description 33
- 102000009066 Hyaluronoglucosaminidase Human genes 0.000 description 27
- 239000003112 inhibitor Substances 0.000 description 25
- 230000000694 effects Effects 0.000 description 21
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 18
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 18
- 210000002744 extracellular matrix Anatomy 0.000 description 18
- 230000001419 dependent effect Effects 0.000 description 16
- 238000002835 absorbance Methods 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 239000000758 substrate Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 102000016942 Elastin Human genes 0.000 description 11
- 108010014258 Elastin Proteins 0.000 description 11
- 102000016943 Muramidase Human genes 0.000 description 11
- 108010014251 Muramidase Proteins 0.000 description 11
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 11
- 229920002549 elastin Polymers 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 239000004325 lysozyme Substances 0.000 description 11
- 229960000274 lysozyme Drugs 0.000 description 11
- 235000010335 lysozyme Nutrition 0.000 description 11
- 229920000642 polymer Polymers 0.000 description 11
- 108090000317 Chymotrypsin Proteins 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 229960002376 chymotrypsin Drugs 0.000 description 10
- 239000012085 test solution Substances 0.000 description 10
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 9
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 9
- 230000001154 acute effect Effects 0.000 description 9
- 230000035876 healing Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- OQZCJRJRGMMSGK-UHFFFAOYSA-M potassium metaphosphate Chemical compound [K+].[O-]P(=O)=O OQZCJRJRGMMSGK-UHFFFAOYSA-M 0.000 description 8
- 235000019828 potassium polyphosphate Nutrition 0.000 description 8
- 230000002797 proteolythic effect Effects 0.000 description 8
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 7
- 102000001554 Hemoglobins Human genes 0.000 description 7
- 108010054147 Hemoglobins Proteins 0.000 description 7
- 229940072056 alginate Drugs 0.000 description 7
- 235000010443 alginic acid Nutrition 0.000 description 7
- 229920000615 alginic acid Polymers 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 7
- 239000012490 blank solution Substances 0.000 description 6
- 238000003182 dose-response assay Methods 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- 239000006260 foam Substances 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 210000004051 gastric juice Anatomy 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- SYZJDGAOLGLIDX-UHFFFAOYSA-N 1-hydroxyazocane Chemical compound ON1CCCCCCC1 SYZJDGAOLGLIDX-UHFFFAOYSA-N 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 5
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 208000004210 Pressure Ulcer Diseases 0.000 description 5
- 102000012479 Serine Proteases Human genes 0.000 description 5
- 108010022999 Serine Proteases Proteins 0.000 description 5
- 208000025865 Ulcer Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 230000002596 correlated effect Effects 0.000 description 5
- AZSFNUJOCKMOGB-UHFFFAOYSA-K cyclotriphosphate(3-) Chemical compound [O-]P1(=O)OP([O-])(=O)OP([O-])(=O)O1 AZSFNUJOCKMOGB-UHFFFAOYSA-K 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000000416 hydrocolloid Substances 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical group [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 150000001340 alkali metals Chemical class 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000000593 degrading effect Effects 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 230000001079 digestive effect Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 210000003238 esophagus Anatomy 0.000 description 4
- 239000004744 fabric Substances 0.000 description 4
- 239000000017 hydrogel Substances 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 210000003097 mucus Anatomy 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 229920000728 polyester Polymers 0.000 description 4
- 229920000098 polyolefin Polymers 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- UGTZMIPZNRIWHX-UHFFFAOYSA-K sodium trimetaphosphate Chemical compound [Na+].[Na+].[Na+].[O-]P1(=O)OP([O-])(=O)OP([O-])(=O)O1 UGTZMIPZNRIWHX-UHFFFAOYSA-K 0.000 description 4
- 230000036269 ulceration Effects 0.000 description 4
- 102000035101 Aspartic proteases Human genes 0.000 description 3
- 108091005502 Aspartic proteases Proteins 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 3
- 241000191938 Micrococcus luteus Species 0.000 description 3
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 3
- 239000004952 Polyamide Substances 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 229920002385 Sodium hyaluronate Polymers 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- SRLROPAFMUDDRC-INIZCTEOSA-N ethyl N-benzoyl-L-tyrosinate Chemical compound C([C@@H](C(=O)OCC)NC(=O)C=1C=CC=CC=1)C1=CC=C(O)C=C1 SRLROPAFMUDDRC-INIZCTEOSA-N 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 210000000867 larynx Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 229920002647 polyamide Polymers 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 239000004814 polyurethane Substances 0.000 description 3
- 229920002635 polyurethane Polymers 0.000 description 3
- 229940010747 sodium hyaluronate Drugs 0.000 description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 3
- 229920001187 thermosetting polymer Polymers 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 101710201511 Coagulation factor X-activating enzyme heavy chain Proteins 0.000 description 2
- 208000008960 Diabetic foot Diseases 0.000 description 2
- 102000015781 Dietary Proteins Human genes 0.000 description 2
- 108010010256 Dietary Proteins Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 101710154810 Snake venom metalloproteinase Proteins 0.000 description 2
- 208000000558 Varicose Ulcer Diseases 0.000 description 2
- 101710197154 Zinc metalloproteinase-disintegrin VMP-II Proteins 0.000 description 2
- 101710112278 Zinc metalloproteinase-disintegrin-like Proteins 0.000 description 2
- 101710200352 Zinc metalloproteinase-disintegrin-like VMP-III Proteins 0.000 description 2
- LGDAGYXJBDILKZ-UHFFFAOYSA-N [2-methyl-1,1-dioxo-3-(pyridin-2-ylcarbamoyl)-1$l^{6},2-benzothiazin-4-yl] 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 LGDAGYXJBDILKZ-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 229920003235 aromatic polyamide Polymers 0.000 description 2
- 239000000987 azo dye Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000008260 defense mechanism Effects 0.000 description 2
- 235000021245 dietary protein Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000006353 environmental stress Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 229920001206 natural gum Polymers 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 235000018343 nutrient deficiency Nutrition 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000011118 polyvinyl acetate Substances 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical group [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 2
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 2
- 210000005070 sphincter Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229920002994 synthetic fiber Polymers 0.000 description 2
- 239000012209 synthetic fiber Substances 0.000 description 2
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 125000001989 1,3-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([H])C([*:2])=C1[H] 0.000 description 1
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 description 1
- RHCFCHADDXGWJE-UHFFFAOYSA-N 1-chloro-3-methylbuta-1,3-diene Chemical compound CC(=C)C=CCl RHCFCHADDXGWJE-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- GDTSJMKGXGJFGQ-UHFFFAOYSA-N 3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical compound O1B([O-])OB2OB([O-])OB1O2 GDTSJMKGXGJFGQ-UHFFFAOYSA-N 0.000 description 1
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 102000004580 Aspartic Acid Proteases Human genes 0.000 description 1
- 108010017640 Aspartic Acid Proteases Proteins 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 208000023514 Barrett esophagus Diseases 0.000 description 1
- 208000023665 Barrett oesophagus Diseases 0.000 description 1
- 101000645291 Bos taurus Metalloproteinase inhibitor 2 Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 229940122097 Collagenase inhibitor Drugs 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 229940122393 Hyaluronidase inhibitor Drugs 0.000 description 1
- 229920000271 Kevlar® Polymers 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920000459 Nitrile rubber Polymers 0.000 description 1
- 229920000784 Nomex Polymers 0.000 description 1
- 229920002292 Nylon 6 Polymers 0.000 description 1
- 229920002302 Nylon 6,6 Polymers 0.000 description 1
- 108010047320 Pepsinogen A Proteins 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 229920005830 Polyurethane Foam Polymers 0.000 description 1
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 101710112987 Zinc metalloproteinase-disintegrin-like crotastatin Proteins 0.000 description 1
- FZQSLXQPHPOTHG-UHFFFAOYSA-N [K+].[K+].O1B([O-])OB2OB([O-])OB1O2 Chemical compound [K+].[K+].O1B([O-])OB2OB([O-])OB1O2 FZQSLXQPHPOTHG-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920006397 acrylic thermoplastic Polymers 0.000 description 1
- TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 108010027597 alpha-chymotrypsin Proteins 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- MTAZNLWOLGHBHU-UHFFFAOYSA-N butadiene-styrene rubber Chemical compound C=CC=C.C=CC1=CC=CC=C1 MTAZNLWOLGHBHU-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000003366 colagenolytic effect Effects 0.000 description 1
- 239000002442 collagenase inhibitor Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- BFMKFCLXZSUVPI-UHFFFAOYSA-N ethyl but-3-enoate Chemical compound CCOC(=O)CC=C BFMKFCLXZSUVPI-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- 239000001761 ethyl methyl cellulose Substances 0.000 description 1
- 102000036444 extracellular matrix enzymes Human genes 0.000 description 1
- 108091007167 extracellular matrix enzymes Proteins 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 231100001014 gastrointestinal tract lesion Toxicity 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940005740 hexametaphosphate Drugs 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229920000554 ionomer Polymers 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 108700041430 link Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 150000007974 melamines Chemical class 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 239000004763 nomex Substances 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001707 polybutylene terephthalate Polymers 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 229920005906 polyester polyol Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000011496 polyurethane foam Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000005033 polyvinylidene chloride Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000005238 principal cell Anatomy 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 150000003355 serines Chemical class 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229920005613 synthetic organic polymer Polymers 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000012815 thermoplastic material Substances 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000003106 tissue adhesive Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Surgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0803284A GB0803284D0 (en) | 2008-02-22 | 2008-02-22 | Enzyme inhibition |
| GB0803283A GB0803283D0 (en) | 2008-02-22 | 2008-02-22 | Enzyme inhibition |
| PCT/GB2009/000504 WO2009104005A1 (en) | 2008-02-22 | 2009-02-23 | Chronic wound treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011512394A true JP2011512394A (ja) | 2011-04-21 |
| JP2011512394A5 JP2011512394A5 (OSRAM) | 2013-08-01 |
Family
ID=40636998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010547251A Pending JP2011512394A (ja) | 2008-02-22 | 2009-02-23 | 慢性創傷の治療 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20110117208A1 (OSRAM) |
| EP (1) | EP2254585A1 (OSRAM) |
| JP (1) | JP2011512394A (OSRAM) |
| WO (1) | WO2009104005A1 (OSRAM) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013011996A1 (ja) * | 2011-07-19 | 2013-01-24 | リジェンティス株式会社 | 酵母菌から抽出されたポリリン酸，ポリリン酸の塩又はポリリン酸の溶媒和物を含むポリリン酸組成物及びその製造方法。 |
| JP2016535041A (ja) * | 2013-10-31 | 2016-11-10 | ベーカー ギウリニ ゲゼルシャフト ミット ベシュレンクテル ハフツングＢＫ Ｇｉｕｌｉｎｉ ＧｍｂＨ | 結晶形ポリリン酸塩を含有する止血剤 |
| JP2022515210A (ja) * | 2018-12-20 | 2022-02-17 | ベーカー ギウリニ ゲーエムベーハー | 出血創傷を処置するための生成物 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5901021B2 (ja) | 2010-01-20 | 2016-04-06 | ケーシーアイ ライセンシング インク | 流体潅流および／または陰圧閉鎖創傷療法のための、親水性フォーム状創傷挿入材を用いた漏出防止包帯システムおよび方法 |
| WO2011125619A1 (ja) * | 2010-04-08 | 2011-10-13 | 国立大学法人旭川医科大学 | 腸管保護剤 |
| GB2561262B (en) * | 2017-07-13 | 2019-03-20 | Dentmed Ltd | A targeted drug delivery pad |
| WO2020039070A1 (en) * | 2018-08-23 | 2020-02-27 | Fibrothelium Gmbh | Preparation of fibroin and therapeutic products made thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09124472A (ja) * | 1995-10-27 | 1997-05-13 | Noevir Co Ltd | コラゲナーゼ阻害剤 |
| JP2001064182A (ja) * | 1999-08-26 | 2001-03-13 | Nissho Corp | スクラルファート懸濁液製剤 |
| WO2001072313A1 (en) * | 2000-03-30 | 2001-10-04 | Kyung Won Medical Co., Ltd. | Polyphosphate for use in promoting wound healing and scar abatement |
| US20020012693A1 (en) * | 2000-02-29 | 2002-01-31 | Cohen Kelman I. | Wound dressings with protease-lowering activity |
| JP2007169171A (ja) * | 2005-12-19 | 2007-07-05 | Regenetiss Kk | 血管新生促進剤 |
| JP2008050290A (ja) * | 2006-08-24 | 2008-03-06 | Regenetiss Kk | コラーゲンの産生を促進する剤、化粧料、及びコラーゲンの製造方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4428984B2 (ja) * | 2003-10-29 | 2010-03-10 | 大正薬品工業株式会社 | ベンズイミダゾール系化合物の安定化経口用組成物 |
| GB2450477A (en) * | 2007-06-18 | 2008-12-31 | Ethicon Inc | Stabilized wound dressing |
-
2009
- 2009-02-23 EP EP09712875A patent/EP2254585A1/en not_active Withdrawn
- 2009-02-23 US US12/918,826 patent/US20110117208A1/en not_active Abandoned
- 2009-02-23 WO PCT/GB2009/000504 patent/WO2009104005A1/en not_active Ceased
- 2009-02-23 JP JP2010547251A patent/JP2011512394A/ja active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09124472A (ja) * | 1995-10-27 | 1997-05-13 | Noevir Co Ltd | コラゲナーゼ阻害剤 |
| JP2001064182A (ja) * | 1999-08-26 | 2001-03-13 | Nissho Corp | スクラルファート懸濁液製剤 |
| US20020012693A1 (en) * | 2000-02-29 | 2002-01-31 | Cohen Kelman I. | Wound dressings with protease-lowering activity |
| WO2001072313A1 (en) * | 2000-03-30 | 2001-10-04 | Kyung Won Medical Co., Ltd. | Polyphosphate for use in promoting wound healing and scar abatement |
| JP2007169171A (ja) * | 2005-12-19 | 2007-07-05 | Regenetiss Kk | 血管新生促進剤 |
| JP2008050290A (ja) * | 2006-08-24 | 2008-03-06 | Regenetiss Kk | コラーゲンの産生を促進する剤、化粧料、及びコラーゲンの製造方法 |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013011996A1 (ja) * | 2011-07-19 | 2013-01-24 | リジェンティス株式会社 | 酵母菌から抽出されたポリリン酸，ポリリン酸の塩又はポリリン酸の溶媒和物を含むポリリン酸組成物及びその製造方法。 |
| JP2016535041A (ja) * | 2013-10-31 | 2016-11-10 | ベーカー ギウリニ ゲゼルシャフト ミット ベシュレンクテル ハフツングＢＫ Ｇｉｕｌｉｎｉ ＧｍｂＨ | 結晶形ポリリン酸塩を含有する止血剤 |
| JP2022515210A (ja) * | 2018-12-20 | 2022-02-17 | ベーカー ギウリニ ゲーエムベーハー | 出血創傷を処置するための生成物 |
| JP7520845B2 (ja) | 2018-12-20 | 2024-07-23 | ベーカー ギウリニ ゲーエムベーハー | 出血創傷を処置するための生成物 |
| US12214103B2 (en) | 2018-12-20 | 2025-02-04 | Bk Giulini Gmbh | Products for treating bleeding wounds |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009104005A1 (en) | 2009-08-27 |
| EP2254585A1 (en) | 2010-12-01 |
| US20110117208A1 (en) | 2011-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2287406T3 (es) | Materiales de vendaje para heridas que comprenden colageno y celulosa oxidada. | |
| JP2011512394A (ja) | 慢性創傷の治療 | |
| JP5860437B2 (ja) | 漏出性または損傷を受けたタイトジャンクションの処置および細胞外マトリクスの増強 | |
| US6187743B1 (en) | Composition and method for enhancing wound healing | |
| Coccheri et al. | Randomised, double blind, multicentre, placebo controlled study of sulodexide in the treatment of venous leg ulcers | |
| US20040001878A1 (en) | Infused wound care dressings | |
| JPS60222425A (ja) | 創傷治癒剤 | |
| JPH11146909A (ja) | 緩衝化された創傷ドレツシング材料 | |
| US20020156437A1 (en) | Removal of targeted proteases with proteinaceous wound dressings containing growth factors | |
| US8507652B2 (en) | Pharmaceutical composition, dressing and method for treating skin lesion, intermediate composition and process for preparing said dressing, and use of cerium salt associated with a collagen matrix | |
| CA3021485C (en) | Methods of debridement of chronic wounds | |
| ES2467668T3 (es) | Composicón farmaceutica, vendaje y método para tratar lesión cutánea, composición intermedia y proceso para preparar dicho vendaje y uso de sal de cerio asociada con una matriz de colágeno | |
| RU2750382C1 (ru) | Способ получения иммобилизованного ферментного препарата на основе коллагеназы, гиалуроновой кислоты и полисахаридов, модифицированных виниловыми мономерами | |
| RU2732224C2 (ru) | Раноочищающая композиция для лечения ран | |
| KR20030068186A (ko) | 단백성 상처 드레싱에 의한 표적화 프로테아제의 제거 | |
| RU2149644C1 (ru) | Способ лечения заболеваний, сопровождающихся образованием гноя и/или некротических тканей | |
| HK1140431B (en) | Treatment of leaky or damaged tight junctions and enhancing extracellular matrix |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120214 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120214 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130125 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130613 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130719 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131018 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131025 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131114 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131121 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131217 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131225 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140120 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140310 |